The Patent Finder

Formulations of Terlipressin

Biovie Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 12,156,898Formulations of Terlipressin
In force
 · High confidence
UsedRemaining
Biovie, Inc.In forceHigh confidence
Application 17/699,019Formulations of Terlipressin
Abandoned
Abandoned Aug 4, 2023
BioVie Inc.AbandonedAbandoned Aug 4, 2023
Application 18/949,355Formulations of Terlipressin
Pending
Not granted
Biovie, Inc.PendingNot granted
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Biovie Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited